DiGeorge Syndrome Critical Region Gene 8 (DGCR8) (N-Term) Peptid
Kurzübersicht für DiGeorge Syndrome Critical Region Gene 8 (DGCR8) (N-Term) Peptid (ABIN8098883)
Target
Quelle
Applikation
-
-
Protein Region
- N-Term
-
Verwendungszweck
- DGCR8 Peptide - N-terminal region
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
This is a synthetic peptide designed for use in combination with anti-DGCR8 antibody ( ARP40984_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Buffer
- Lyophilized powder
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
-
-
- DGCR8 (DiGeorge Syndrome Critical Region Gene 8 (DGCR8))
-
Hintergrund
-
Targeted Subunit: DGCR8
Background Information: DGCR8 contains 2 DRBM (double-stranded RNA-binding) domains and 1 WW domain. It may play a part in the etiology of the velocardiofacial/DiGeorge syndrome (VCFS/DGS), a developmental disorder characterized by structural and functional palate anomalies, conotruncal cardiac malformations, immunodeficiency, hypocalcemia, and typical facial anomalies.
Alternative Symbols: C22orf12, DGCRK6, Gy1, pasha
-
Molekulargewicht
- 85kDa
-
Gen-ID
- 54487
-
NCBI Accession
- NP_073557
-
UniProt
- Q8WYQ5
Target
-
